TARO
GenericsTARO is a generic drug manufacturer focused on Neurology, Dermatology, Cardiovascular.
TARO's Key Drugs
TARO's core commercial portfolio centers on BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, spanning Neurology and Dermatology — its most strategically important drugs approved in the last 15 years.
TARO's Recent FDA Approvals
New NDA/BLA approvals for TARO over the last two years — novel drugs only, excluding generics and label supplements.
TARO's Therapeutic Areas
TARO's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Dermatology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TARO's Top Competitors
TARO's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TARO Pipeline Snapshot
Active clinical trials for TARO across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (2)
Company Info
- First Approval
- 1977-02-28
- Latest
- 2026-06-15
- Applications
- 114